In a recent editorial in EyeNet on the importance of collaboration in successful research, past-president of the American Academy of Ophthalmology, Ruth Williams, M.D. cites Dr. Novack. Dr. Novack stated “…You cannot be successful unless you realize that you do NOT know everything”. Further she states that “…major breakthroughs usually require a multi-disciplinary approach, ophthalmic researcher must recognize and woo individuals who may not currently be working on vision research”. A prime example of this is the Glaucoma Research Foundation’s “Catalyst for a Cure”.
Dr. Novack’s article on pharmacological prophylaxis of myopia was published in a special issue of Eye and Contact Lens. This issue (Volume 44 / Issue Number 4, July 2018) features articles on Myopia Control: Current thoughts and future research. It was edited by Drs. Penny A. Asbell and Kazuo Tsubota. The publication is based upon a symposium held in November 2017 in Tokyo at Keio University. The issue includes authors from a wide variety of perspectives. All agree – myopia is an epidemic that will continue to take medical resources to deal with the increasing number of affected patients worldwide.
Three researchers published an article on research economics in Science on 7 April. Over a 27-year analysis period, while only 10% of NIH grants generate a patent directly, 30% generate articles that are subsequently cited by a patent. This “indirect” statistics suggests a greater impact of government funded research than previously thought. Oh, and there was no systematic difference between “basic” and “applied” research in these statistics.
Dr. Novack was selected as a member of the Glaucoma Research Society, a public interest, nonprofit scientific association of outstanding glaucoma researchers. The society provides a forum to discuss and stimulate compelling research to prevent glaucoma-related disability worldwide; the organization consists of fewer than 100 scientists whose investigations lead the field of glaucoma.